Erica Weaver
Nurse Practitioner · Bay City, MINPI 1093225450
Payments from drug & device makers
Across 122 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$248
- AbbVie$228
- Lilly USA, LLC$223
- Pfizer$143
- Novartis$122
- AstraZeneca$120
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,20595%
- Education$1135%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 10 | $248 |
| AbbVie | 10 | $228 |
| Lilly USA, LLC | 14 | $223 |
| Pfizer | 8 | $143 |
| Novartis | 7 | $122 |
| AstraZeneca | 8 | $120 |
| Novo Nordisk | 7 | $109 |
| Bayer | 5 | $103 |
| Boston Scientific | 1 | $92 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $92 |
| GSK | 6 | $90 |
| Johnson & Johnson | 5 | $89 |
| Abbott | 5 | $83 |
| Axsome Therapeutics, Inc. | 4 | $74 |
| Dexcom, Inc. | 3 | $51 |
| Nestle Healthcare Nutrition Inc. | 2 | $51 |
| Edwards Lifesciences | 1 | $44 |
| Astellas Pharma US Inc | 2 | $43 |
| Amarin Pharma, Inc. | 2 | $34 |
| Nevro Corp. | 1 | $30 |
| Amgen | 2 | $28 |
| Exact Sciences | 2 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Biogen | 1 | $24 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $20 |
| Halozyme Inc | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Shield Therapeutics Inc | 1 | $19 |
| Antares Pharma, Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Corium, LLC | 1 | $14 |
How this compares
$2,318 in reported general payments places this provider in the 90th percentile of 3,351 nurse practitioner providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 216 | $269,390 |
| EliquisApixaban | 198 | $242,654 |
| OzempicSemaglutide | 124 | $148,452 |
| JardianceEmpagliflozin | 76 | $112,231 |
| TrulicityDulaglutide | 45 | $68,526 |
| JanuviaSitagliptin Phosphate | 52 | $62,044 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $52,002 |
| FarxigaDapagliflozin Propanediol | 42 | $41,288 |
| XareltoRivaroxaban | 35 | $41,095 |
| Bydureon BciseExenatide Microspheres | 19 | $21,755 |
| InvokanaCanagliflozin | 11 | $17,941 |
| LinzessLinaclotide | 17 | $16,266 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 77 | $14,732 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $14,112 |
| Atorvastatin Calcium | 816 | $12,783 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $223 | $337,915261 claims |
| PfizerEliquis, Nurtec Odt, Paxlovid | $143 | $264,857238 claims |
| Novo NordiskOzempic | $109 | $148,452124 claims |
| Boehringer IngelheimJardiance | $248 | $112,23176 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $90 | $66,11378 claims |
| Johnson & JohnsonXarelto, Invokana | $89 | $59,03546 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $120 | $57,73567 claims |
| AbbVieLinzess | $228 | $16,26617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,351 nurse practitioner providers in Michigan.
Other nurse practitioner in Bay City
- Erin KoepplingerBay City$10K
- Jessica LauriaBay City$10K
- Davida KrugerDetroit$1.8M
- Kari HillSpring Lake$426K
- Kyle FarrPlymouth$243K
- Linda SpencerTroy$217K
- Ellen DillardDetroit$168K
- Golbon AghamohammadiDetroit$157K
- Abubakir BabanDearborn$143K
- Elizabeth KirshnerAnn Arbor$119K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.